Weight-Loss drug and IUD combo may help obese women avoid hysterectomy
NCT ID NCT07107334
First seen Jan 04, 2026 · Last updated Jun 09, 2026 · Updated 25 times
Summary
This pilot study tests whether adding a GLP-1RA weight-loss drug (like semaglutide) to a levonorgestrel IUD can help obese patients with endometrial precancer avoid hysterectomy or preserve fertility. About 20 participants will be followed for up to 12 months to see if the treatment clears the precancerous cells and allows them to safely pursue pregnancy or surgery. The goal is to find a less invasive option for those who are not good candidates for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida
RECRUITINGGainesville, Florida, 32608, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.